Title: 2025-2026 Regular Session SB 866 PN 1082 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN1082
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session SB 866 PN 1082 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1082 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.866 Session of 2025 INTRODUCED BY BROOKS, MASTRIANO, TARTAGLIONE AND BOSCOLA, JULY 24, 2025 REFERRED TO AGRICULTURE AND RURAL AFFAIRS, JULY 24, 2025 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 4(3) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended by adding subclauses to read:Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated.* * *1234567891011121314151617181920212223 (3) Schedule III--In determining that a substance comes within this schedule, the secretary shall find: a potential for abuse less than the substances listed in Schedules I and II; well documented and currently accepted medical use in the United States; and abuse may lead to moderate or low physical dependence or high psychological dependence. The following classes of controlled substances are included in this schedule:* * *(xii) Medetomidine, including any compound, mixture or preparation which contains any quantity of the substances referred to in this clause.(xiii) Medetomidine as described in subclause (xii) is not a controlled substance when used in any of the following manners:1. Dispensing or prescribing for, or administering to, a nonhuman species of a drug containing medetomidine that:(A) has been approved by the United States Secretary of Health and Human Services under 21 U.S.C. § 360b (relating to new animal drugs); or(B) is authorized under 21 U.S.C. § 360b(a)(4).2. The manufacturing, distribution or use of medetomidine as an active pharmaceutical ingredient for manufacturing an animal drug approved under 21 U.S.C. § 360b or an animal drug that has been issued an investigation use exemption under 21 U.S.C. § 360b(j).3. The manufacturing, distribution or use of a medetomidine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarians.4. Any other use approved or authorized under 21 U.S.C. Ch. 9 (relating to Federal Food, Drug, and Cosmetic Act).5. Another use approved or permissible under Federal or 20250SB0866PN1082 - 2 - 123456789101112131415161718192021222324252627282930 State law.* * *Section 2. Section 13.9 of the act, added May 15, 2024 (P.L.364, No.17), is amended to read:Section 13.9. Secure Storage of Medetomidine and Xylazine.--A practitioner who is a veterinarian shall comply with the provisions of section 4(a)(5) of the act of September 27, 1961 (P.L.1700, No.699), known as the "Pharmacy Act," for the storage and protection of medetomidine and xylazine.Section 3. This act shall take effect immediately.20250SB0866PN1082 - 3 - 12345678910


================================================================================

Raw Text:
2025-2026 Regular Session SB 866 PN 1082 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1082 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE BILL No.866 Session of 2025 INTRODUCED BY BROOKS, MASTRIANO, TARTAGLIONE AND BOSCOLA, JULY 24, 2025 REFERRED TO AGRICULTURE AND RURAL AFFAIRS, JULY 24, 2025 AN ACTAmending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for schedules of controlled substances and for secure storage of xylazine; and adding provisions relating to medetomidine.The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows:Section 1. Section 4(3) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, is amended by adding subclauses to read:Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated.* * *1234567891011121314151617181920212223 (3) Schedule III--In determining that a substance comes within this schedule, the secretary shall find: a potential for abuse less than the substances listed in Schedules I and II; well documented and currently accepted medical use in the United States; and abuse may lead to moderate or low physical dependence or high psychological dependence. The following classes of controlled substances are included in this schedule:* * *(xii) Medetomidine, including any compound, mixture or preparation which contains any quantity of the substances referred to in this clause.(xiii) Medetomidine as described in subclause (xii) is not a controlled substance when used in any of the following manners:1. Dispensing or prescribing for, or administering to, a nonhuman species of a drug containing medetomidine that:(A) has been approved by the United States Secretary of Health and Human Services under 21 U.S.C. § 360b (relating to new animal drugs); or(B) is authorized under 21 U.S.C. § 360b(a)(4).2. The manufacturing, distribution or use of medetomidine as an active pharmaceutical ingredient for manufacturing an animal drug approved under 21 U.S.C. § 360b or an animal drug that has been issued an investigation use exemption under 21 U.S.C. § 360b(j).3. The manufacturing, distribution or use of a medetomidine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarians.4. Any other use approved or authorized under 21 U.S.C. Ch. 9 (relating to Federal Food, Drug, and Cosmetic Act).5. Another use approved or permissible under Federal or 20250SB0866PN1082 - 2 - 123456789101112131415161718192021222324252627282930 State law.* * *Section 2. Section 13.9 of the act, added May 15, 2024 (P.L.364, No.17), is amended to read:Section 13.9. Secure Storage of Medetomidine and Xylazine.--A practitioner who is a veterinarian shall comply with the provisions of section 4(a)(5) of the act of September 27, 1961 (P.L.1700, No.699), known as the "Pharmacy Act," for the storage and protection of medetomidine and xylazine.Section 3. This act shall take effect immediately.20250SB0866PN1082 - 3 - 12345678910